Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Serial intravascular ultrasound evaluation of the DESolve™ novolimus-eluting bioresorbable coronary scaffold system.

Barreira G, Costa JR Jr, Costa R, Staico R, Chamie D, Slhessarenko JR, Tanajura LF, Abizaid A, Sousa A, Abizaid A.

Catheter Cardiovasc Interv. 2018 Mar 9. doi: 10.1002/ccd.27591. [Epub ahead of print]

PMID:
29521477
2.

Long-Term Follow-Up of Patients after Percutaneous Coronary Intervention with Everolimus-Eluting Bioresorbable Vascular Scaffold.

Meneguz-Moreno RA, Costa JR Junior, Moscoso FA, Staico R, Tanajura LF, Centemero MP, Chaves AJ, Abizaid AC, Sousa AG, Abizaid AA.

Arq Bras Cardiol. 2017 Feb;108(2):109-115. doi: 10.5935/abc.20160202. Epub 2017 Jan 9. English, Portuguese.

3.

Vessel remodeling and plaque distribution in side branch of complex coronary bifurcation lesions: a grayscale intravascular ultrasound study.

Costa RA, Feres F, Staico R, Abizaid A, Costa JR Jr, Siqueira D, Tanajura LF, Damiani LP, Sousa A, Sousa JE, Colombo A.

Int J Cardiovasc Imaging. 2013 Dec;29(8):1657-66. doi: 10.1007/s10554-013-0263-1. Epub 2013 Jul 19.

PMID:
23868286
4.

Correlation between plaque composition as assessed by virtual histology and C-reactive protein.

Siqueira DA, Sousa AG, Costa Junior Jde R, Costa RA, Staico R, Tanajura LF, Centemero MP, Feres F, Abizaid AA, Sousa JE.

Arq Bras Cardiol. 2013 Jul;101(1):78-86. Epub 2013 Jun 11. English, Portuguese.

5.

Very long-term follow-up of strut apposition and tissue coverage with Biolimus A9 stents analyzed by optical coherence tomography.

Staico R, Costa MA, Chamié D, Bezerra H, Armaganijan LV, Costa RA, Costa JR, Siqueira D, Centemero M, Chaves Á, Tanajura LF, Abizaid A, Feres F, Sousa JE, Sousa AG.

Int J Cardiovasc Imaging. 2013 Jun;29(5):977-88. doi: 10.1007/s10554-013-0188-8. Epub 2013 Mar 3.

PMID:
23456358
6.

Serial greyscale and radiofrequency intravascular ultrasound assessment of plaque modification and vessel geometry at proximal and distal edges of bare metal and first-generation drug-eluting stents.

Ribamar Costa J Jr, Abizaid A, Sousa A, Siqueira D, Chamié D, Feres F, Costa R, Staico R, Maldonado G, Centemero M, Tanajura LF, Viana R, Chaves Á, Abizaid A, Sousa JE.

EuroIntervention. 2012 Jun 20;8(2):225-34. doi: 10.4244/EIJV8I2A36.

7.

One-year results of the INSPIRE trial with the novel MGuard stent: serial analysis with QCA and IVUS.

Costa JR Jr, Abizaid A, Feres F, Costa R, Staico R, Siqueira D, Centemero M, Tanajura LF, Sousa A, Sousa JE.

Catheter Cardiovasc Interv. 2011 Dec 1;78(7):1095-100. doi: 10.1002/ccd.22980. Epub 2011 Jul 22.

PMID:
21786400
8.

Serial angiographic and intravascular ultrasound evaluation to interrogate the presence of late "catch-up" phenomenon after Cypher® sirolimus-eluting stent implantation.

Chamié D, Abizaid A, Costa JR Jr, Feres F, Almiro da Silva JF, Mattos LA, Staico R, Costa RA, Abizaid A, Tanajura LF, Sousa AG, Sousa JE.

Int J Cardiovasc Imaging. 2011 Jul;27(6):867-74. doi: 10.1007/s10554-010-9723-z. Epub 2010 Nov 17.

PMID:
21082255
9.

Serial angiography and intravascular ultrasound: results of the SISC Registry (Stents In Small Coronaries).

Chamié D, Costa JR Jr, Abizaid A, Feres F, Staico R, Devito F, Costa RA, Abizaid A, Tanajura LF, Sousa AG, Fitzgerald PJ, Whitbourn RJ, Sousa JE.

JACC Cardiovasc Interv. 2010 Feb;3(2):191-202. doi: 10.1016/j.jcin.2009.11.014.

10.

Angiographic and intravascular ultrasound findings following implantation of the Endeavor zotarolimus-eluting stents in patients from the real-world clinical practice.

Feres F, Andrade PB, Costa RA, de Ribamar Costa J Jr, Abizaid A, Staico R, Tanajura LF, Siqueira D, Maia JP, Lasave L, Sousa AG, Sousa JE.

EuroIntervention. 2009 Aug;5(3):355-62.

PMID:
19736161
11.

1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial.

Costa JR Jr, Abizaid A, Costa R, Feres F, Tanajura LF, Abizaid A, Maldonado G, Staico R, Siqueira D, Sousa AG, Bonan R, Sousa JE.

JACC Cardiovasc Interv. 2009 May;2(5):422-7. doi: 10.1016/j.jcin.2009.02.009.

12.

Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system.

Costa JR Jr, Abizaid A, Costa R, Feres F, Tanajura LF, Abizaid A, Mattos LA, Staico R, Siqueira D, Sousa AG, Bonan R, Sousa JE.

JACC Cardiovasc Interv. 2008 Oct;1(5):545-51. doi: 10.1016/j.jcin.2008.07.003.

13.

EXCELLA First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions.

Costa JR Jr, Abizaid A, Feres F, Costa R, Seixas AC, Maia F, Abizaid A, Tanajura LF, Staico R, Siqueira D, Meredith L, Bhat V, Yan J, Ormiston J, Sousa AG, Fitzgerald P, Sousa JE.

EuroIntervention. 2008 May;4(1):53-8.

PMID:
19112779
14.

Clinical and angiographic results of percutaneous coronary revascularization using a trilayer stainless steel-tantalum-stainless steel phosphorylcholine-coated stent: the TriMaxx trial.

Abizaid A, Popma JJ, Tanajura LF, Hattori K, Solberg B, Larracas C, Feres F, Costa Jde R Jr, Schwartz LB.

Catheter Cardiovasc Interv. 2007 Dec 1;70(7):914-9.

PMID:
18044791
15.

[Relationship between plasma C-reactive protein level and neointimal hyperplasia volume in patients with zotarolimus-eluting stents. Volumetric analysis by three-dimensional intracoronary ultrasound].

Lasave LI, Abizaid AA, Paiva e Maia J, de Ribamar Costa J Jr, Feres F, Mattos LA, Abizaid AS, Siqueira DA, Tanajura LF, Staico R, Beraldo de Andrade P, Braga SN, Sousa AG, Sousa JE.

Rev Esp Cardiol. 2007 Sep;60(9):923-31. Spanish.

16.

Drug-eluting stents vs bare metal stents for the treatment of large coronary vessels.

Quizhpe AR, Feres F, de Ribamar Costa J Jr, Abizaid A, Maldonado G, Costa R, Abizaid A, Cano M, Moreira AC, Staico R, Mattos LA, Tanajura LF, Chaves A, Centemero M, Sousa AM, Sousa JE.

Am Heart J. 2007 Aug;154(2):373-8.

PMID:
17643591
17.

A three-dimensional intravascular ultrasound comparison between the new zotarolimus-eluting stent (ZoMaxx) and the non-drug-eluting TriMaxx stent.

Lasave LI, Costa Jde R Jr, Abizaid AA, Feres F, Tanajura LF, Staico R, Abizaid AA, Beraldo P, Sousa AM, Sousa JE.

J Invasive Cardiol. 2007 Jul;19(7):303-8.

18.

Late vascular response at the edges of sirolimus analogous-eluting stents in diabetic patients: An intravascular ultrasound study.

Lasave LI, Abizaid AA, de Ribamar Costa J Jr, Tanajura LF, Feres F, Abizaid AS, Siqueira D, Staico R, Sousa AG, Sousa JE.

Catheter Cardiovasc Interv. 2007 Oct 1;70(4):498-503.

PMID:
17503511
19.

Percutaneous coronary revascularization using a trilayer metal phosphorylcholine-coated zotarolimus-eluting stent.

Abizaid A, Lansky AJ, Fitzgerald PJ, Tanajura LF, Feres F, Staico R, Mattos L, Abizaid A, Chaves A, Centemero M, Sousa AG, Sousa JE, Zaugg MJ, Schwartz LB.

Am J Cardiol. 2007 May 15;99(10):1403-8. Epub 2007 Apr 4.

PMID:
17493469
20.

Late incomplete apposition after drug-eluting stent implantation: incidence and potential for adverse clinical outcomes.

Siqueira DA, Abizaid AA, Costa Jde R, Feres F, Mattos LA, Staico R, Abizaid AA, Tanajura LF, Chaves A, Centemero M, Sousa AG, Sousa JE.

Eur Heart J. 2007 Jun;28(11):1304-9. Epub 2007 May 3.

PMID:
17478457

Supplemental Content

Loading ...
Support Center